The Future of Parenteral Nutrition: Key Players, Disease Specific Opportunities and Market Forecasts
NEW YORK, Oct. 10, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Future of Parenteral Nutrition: Key players, disease specific opportunities and market forecasts
http://www.reportlinker.com/p0330665/The-Future-of-Parenteral-Nutrition-Key-players-disease-specific-opportunities-and-market-forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology
In 2009, approximately 390,000 patients in the major markets of the US, EU and Canada used parenteral nutrition products, accounting for total product sales of $1.3b. Through 2014, the total number of parenteral nutrition users in will rise by 10.0% per year to 628,000 and sales will expand by 11.3% per year, reflecting only nominal annual price increases. Four manufacturers currently jockey for share in this closely held market: market leader Baxter, enteral and parenteral products suppliers Fresenius Kabi and B. Braun, and Hospira. Although the introduction of new parenteral solutions is infrequent, these four players are differentiating themselves through hardware improvements, expanded pediatric labeling, new product formats and enhanced systems and services for home use. This report investigates these market opportunities, as well as emerging product development trend such as combination products and products developed for specialized disease populations. In each region profiled ?US, Canada and EU ?it investigates near and long term opportunities as well as recent product launches. Finally, it summarizes these opportunities in the context of product development initiatives currently underway at the leading manufacturers.
This report investigates these market opportunities, as well as emerging product development trend such as combination products and products developed for specialized disease populations. In each region profiled – US, Canada and EU – it investigates near and long term opportunities as well as recent product launches. rbcn0013
Scope of this research
* Develop deeper insight into the size and growth of the US, Canadian and EU parenteral nutrition industry, as well as individual EU country markets.
* Understand key product development trends in the parenteral nutrition market and the R&D strategies of the major players.
* Identify short and long term market opportunities in each region.
* Anticipate future parenteral nutrition market needs in light of the drivers and restraints acting upon the market.
* Describes the major market drivers and restraints in the US, Canada and EU, with detail provided for Germany, France, UK, Italy, Spain & Poland
Research and analysis highlights
Growth will be driven by increasing usage as the populations in these regions continue to age and incidence of conditions associated with parenteral nutrition, such as cancer and gastrointestinal disease, rises.
The total US, Canadian and EU parenteral nutrition market reached $1.3b in 2009 and is growing by 11.3% per year to reach $2.3bn in 2014. In 2009, Baxter led the market with 29.5% share, followed by Fresenius Kabi with 28.7%, B. Braun Melsungen with 22.2% and Hospira with 16.9%.
Major near term opportunities for new products include improved hardware and accessories, and products developed for home use. Important new recent launches include the triple-chamber bag, which three of the top four manufacturers now offer.
Key reasons to purchase this research
* What are the regional differences between the parenteral markets in the US, Canada, Germany, France, UK, Italy, Spain and Poland?
* Which companies are current and future key players and what are the issues driving new product development?
* What is limiting greater parenteral nutrition usage and how are prescribing decisions made by clinicians?
* What emerging products could significantly impact parenteral nutrition sales & what new product initiatives are being pursued by the leading players?
* What will the size and growth of the global parenteral nutrition market be through 2014?
Table of Contents
About the author 2
Disclaimer 2
Executive summary 9
Introduction 9
Parenteral nutrition in the US & Canada 10
Parenteral nutrition in the EU 11
Opportunities in parenteral nutrition 12
Chapter 1 Introduction 13
Summary 13
Introduction 14
Parenteral vs. enteral nutrition 14
Major disease populations for parenteral nutrition 17
Cancer patients 18
Parenteral nutrition for cancer patients 20
Gastrointestinal disease patients 22
Parenteral nutrition for GI disease patients 23
AIDS patients 24
Parenteral nutrition for AIDS patients 25
Environments for parenteral nutrition 26
Inpatient environments 26
Outpatient environments 26
Major types of parenteral nutrition & product ingredients 28
Central vs. peripheral parenteral nutrition 28
Parenteral vs. total parenteral nutrition (TPN) 30
Standardized vs. individualized formulas 30
Pediatric patients 31
Products and ingredients 31
Partial parenteral nutrition 32
Total parenteral nutrition 33
Opportunities to incorporate medications into products 33
Alternatives to parenteral nutrition 34
Market summary 36
Conclusion 41
Chapter 2 Parenteral nutrition in the US & Canada 42
Summary 42
Introduction 43
Regulation 43
Insurance reimbursement 43
User populations 49
Parenteral nutrition in the US 50
Key products and players 50
Sales and market share, 2009–2014 51
Sales by disease population 55
How clinicians select products 56
New product development 57
Opportunities 59
Near term (2010–2012) 59
Long term (2013–2014) 60
Parenteral nutrition in Canada 62
Key products and players 63
Sales and market share, 2009–2014 63
Sales by disease population 65
How clinicians select products 65
New product development 66
Opportunities 67
Near term (2010–2012) 67
Long term (2013–2014) 67
Conclusions 67
Chapter 3 Parenteral nutrition in the EU 68
Summary 68
Introduction 69
Regulation 69
Insurance Reimbursement 70
User populations 70
Parenteral nutrition in the EU 71
Key products and players 72
Sales and market share 80
Total sales 81
Germany 82
France 83
UK 85
Italy 86
Spain 87
Poland 89
Sales by disease population 90
Germany 91
France 91
UK 92
Italy 93
Spain 93
Poland 94
How clinicians select products 94
New product development 95
Opportunities 96
Near term (2010–2012) 96
Long term (2013–2014) 96
Conclusions 98
Chapter 4 Opportunities in parenteral nutrition 99
Summary 99
Introduction 100
New products and other opportunities by product 100
Improved hardware and accessories 101
Automation 102
Non-intravenous product formats 103
Products for selected disease populations 104
Products designed for home use 106
Combination products 107
Pediatric products 107
Product development strategies of leading parenteral nutrition players 108
B. Braun 109
Baxter 110
Fresenius Kabi 111
Hospira 112
Conclusion 114
Appendix 115
Scope 115
Methodology 115
Primary research 115
Secondary research 115
Glossary/Abbreviations 115
References 117
Table of figures
Figure 1: Advantages and disadvantages of parenteral nutrition 16
Figure 2: Major routes of parenteral nutrition 29
Figure 3: Number of parenteral nutrition patients in the US, Canada & EU, 2009– 14 37
Figure 4: Sales of parenteral nutrition products ($m), in the US Canada & EU, 2009– 14 38
Figure 5: Sales of parenteral nutrition products ($m), in the US, Canada and EU by disease population, 2009 - 2014 39
Figure 6: Sales of parenteral nutrition products ($m), in the US, Canada and EU by major manufacturer, 2009 40
Figure 7: Number of parenteral nutrition patients in the US and Canada, 2009– 14 49
Figure 8: US parenteral nutrition market ($m), 2009– 14 52
Figure 9: Leading US parenteral nutrition players, 2009 55
Figure 10: US parenteral nutrition market by disease population ($m), 2009– 14 56
Figure 11: Triple-chamber bag, dual-chamber bag and traditional bag 59
Figure 12: Canadian parenteral nutrition market ($m), 2009–2014 64
Figure 13: Leading Canadian parenteral nutrition players, 2009 65
Figure 14: Canadian parenteral nutrition market ($m), by disease population, 2009– 14 66
Figure 15: Number of EU parenteral nutrition patients, 2009–14 70
Figure 16: EU country potential for parenteral nutrition, 2010 78
Figure 17: Total EU parenteral nutrition market ($m), 2009– 14 80
Figure 18: Leading EU parenteral nutrition players ($m), 2009 81
Figure 19: German parenteral nutrition market and patients ($m), 2009– 14 83
Figure 20: French parenteral nutrition market and patients ($m), 2009– 14 84
Figure 21: UK parenteral nutrition market and patients ($m), 2009– 14 86
Figure 22: Italian parenteral nutrition market and patients ($m), 2009– 14 87
Figure 23: Spanish parenteral nutrition market and patients ($m), 2009– 14 88
Figure 24: Polish parenteral nutrition market and patients ($m), 2009– 14 89
Figure 25: EU parenteral nutrition market by disease population ($m), 2009– 14 90
Figure 26: EU hospital stays vs. home care patients, 1990–2010 97
Figure 27: Parenteral nutrition opportunities by product type, 2010 101
Figure 28: TPNstation from Health Robotics, 2010 103
Figure 29: Strategy and product development activities of leading parenteral nutrition product manufacturers, 2010 109
Figure 30: Ambix-Active infusion pump from Fresenius Kabi 113
Table of tables
Table 1: Indications and contraindications for enteral and parenteral nutrition 15
Table 2: Patients using parenteral nutrition by condition, 2010 18
Table 3: Inpatient care facilities in the US, Canada and EU, 2010 27
Table 4: Basic adult daily requirements for TPN, 2010 34
Table 5: Basic adult daily requirements for TPN, 2010 (cont.) 35
Table 6: Sales of parenteral nutrition products ($m), by region and major manufacturer, 2009 41
Table 7: CMS reimbursement schedule for parenteral nutrition products and accessories, 2009 48
Table 8: Leading US parenteral nutrition products, 2010 51
Table 9: Leading Canadian parenteral nutrition products, 2010 63
Table 10: Leading EU parenteral nutrition products, 2010 73
Table 11: Demographic data for EU member countries 2006 76
Table 12: Healthcare data for EU member countries 2006 77
Table 13: Malnutrition in the EU by country, 2010 79
Table 14: Selected disease specific clinical nutrition products, 2010 105
To order this report:
Drug Delivery Technology Industry: The Future of Parenteral Nutrition: Key players, disease specific opportunities and market forecasts
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article